Trial Profile
An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.
- 23 Oct 2013 New trial record